Compounds > 2-3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline

2-3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline and Migraine-Disorders

2-3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline has been researched along with Migraine-Disorders* in 1 studies

Other Studies

1 other study(ies) available for 2-3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline and Migraine-Disorders

Article	Year
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. Journal of medicinal chemistry, 2002, Sep-26, Volume: 45, Issue:20 Amino diacid 3, a highly selective competitive GluR5 kainate receptor antagonist, exhibited high GluR5 receptor affinity and selectivity over other glutamate receptors. Its diethyl ester prodrug 4 was orally active in two models of migraine: the neurogenic dural plasma protein extravasation model and the nucleus caudalis c-fos expression model. These data suggest that a GluR5 kainate receptor antagonist might be an efficacious antimigraine therapy with a novel mechanism of action. Topics: Acute Disease; Administration, Oral; Animals; Biological Availability; Calcium; Carboxylic Acids; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Esters; Excitatory Amino Acid Antagonists; Humans; Isoquinolines; Migraine Disorders; Prodrugs; Radioligand Assay; Rats; Rats, Wistar; Receptors, Kainic Acid	2002

Article

Year

Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.

Journal of medicinal chemistry, 2002, Sep-26, Volume: 45, Issue:20

Amino diacid 3, a highly selective competitive GluR5 kainate receptor antagonist, exhibited high GluR5 receptor affinity and selectivity over other glutamate receptors. Its diethyl ester prodrug 4 was orally active in two models of migraine: the neurogenic dural plasma protein extravasation model and the nucleus caudalis c-fos expression model. These data suggest that a GluR5 kainate receptor antagonist might be an efficacious antimigraine therapy with a novel mechanism of action.

Topics: Acute Disease; Administration, Oral; Animals; Biological Availability; Calcium; Carboxylic Acids; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Esters; Excitatory Amino Acid Antagonists; Humans; Isoquinolines; Migraine Disorders; Prodrugs; Radioligand Assay; Rats; Rats, Wistar; Receptors, Kainic Acid

2002